Core Insights - Treatment.com AI Inc. has launched its latest Medical Education Suite (MES), an AI-powered platform for clinical skills assessment, successfully deployed at the University of Minnesota Medical School [1][5] - The MES aims to enhance the delivery and evaluation of Objective Structured Clinical Examinations (OSCEs) by providing scalable, rigorous, and cost-effective solutions [1][5] Group 1: Deployment and Implementation - The MES was deployed with over 240 third-year medical students, marking the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM) [2][5] - The deployment demonstrated complete technical reliability and seamless integration into the existing OSCE workflow at the University of Minnesota [2][6] Group 2: Features and Benefits - The MES incorporates AI-simulated patients and real-time scoring, which supports faster, accurate, and objective assessments, potentially leading to approximately 40% cost savings for the University of Minnesota [5][6] - The platform is designed to reduce faculty preparation and administrative workload while providing objective evaluations aligned with clinical learning objectives [6][8] Group 3: Educational Impact - Early feedback indicates that the MES enhances the student learning experience and strengthens the reliability of OSCE results, helping students build stronger clinical skills [4][6] - The platform combines AI-simulated patients with automated feedback, allowing faculty to assess various competencies such as diagnostic reasoning and clinical prioritization [4][6] Group 4: Future Prospects - Treatment.com AI is engaging with various medical schools to extend the MES offering across North America, the UK, and other international OSCE markets [8] - Preliminary results of the MES's accuracy and precision were presented at the AAMC's 2025 Group on Information Resources meeting, with further scientific publications planned [7]

Core Insights - Treatment.com AI Inc. has launched its latest Medical Education Suite (MES), an AI-powered platform aimed at enhancing clinical skills assessment in medical education [1][7] - The University of Minnesota Medical School has successfully deployed the MES with over 240 third-year medical students, marking a significant step in the integration of AI in medical training [2][4] Company Overview - Treatment.com AI utilizes artificial intelligence and clinical expertise to address inefficiencies in the healthcare sector, developing the Global Library of Medicine (GLM) to support healthcare professionals [9] - The MES is designed to provide scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs), improving the educational experience for medical students [1][3] Deployment and Features - The MES was implemented seamlessly into the University of Minnesota's existing OSCE workflow, demonstrating complete technical reliability during deployment [2][4] - Key features of the MES include AI-simulated patients, real-time scoring, and automated feedback, which enhance the objectivity and consistency of student evaluations [4][8] Cost Efficiency - The University of Minnesota reported approximately 40% cost savings in administrative expenses due to the implementation of the MES [8][7] - The platform aims to reduce faculty preparation and administrative workload while aligning evaluations with clinical learning objectives [8][4] Future Prospects - Treatment.com AI is actively engaging with various educational institutions to expand the MES offering across North America, the UK, and other international markets [6][7] - Preliminary results regarding the accuracy and precision of the GLM as applied in the MES were presented at the AAMC's 2025 Group on Information Resources meeting, with further scientific publications in preparation [5][7]

Core Insights - Treatment.com AI Inc.'s Rocket Doctor has been selected for the 2025 Heal.LA Bioscience and Healthcare Accelerator Cohort, aimed at enhancing access to healthcare in underserved communities [2][3] - The accelerator program will provide Rocket Doctor with strategic mentorship, regulatory support, and access to a network of healthcare leaders and potential partners, facilitating its growth in the U.S. market [4][8] - Rocket Doctor's innovative, physician-led platform utilizes AI-enabled tools to deliver remote care, focusing on communities with limited access to healthcare services [3][5] Company Overview - Rocket Doctor is a technology-driven digital health platform that allows healthcare providers to manage virtual or hybrid practices, aiming to redefine modern healthcare by removing barriers to care [6][8] - The platform is designed to empower healthcare providers with AI-powered tools, enabling them to deliver high-quality care remotely, particularly to underserved populations across North America [6][10] - Treatment.com AI is focused on improving healthcare efficiency through its Global Library of Medicine, which supports healthcare professionals by reducing administrative burdens and enhancing patient care quality [10]

Core Insights - Treatment.com AI Inc.'s Rocket Doctor has been selected for the 2025 Heal.LA Bioscience and Healthcare Accelerator, aimed at enhancing access to healthcare in underserved communities [2][3] - The accelerator will provide Rocket Doctor with strategic mentorship, regulatory support, and access to a network of healthcare leaders and potential partners, facilitating its growth in the U.S. market [4][8] - Rocket Doctor's innovative, physician-led platform utilizes AI-enabled tools to deliver remote care, focusing on communities with limited access to healthcare [3][5] Company Overview - Rocket Doctor is a technology-driven digital health platform that allows healthcare providers to manage virtual or hybrid practices, aiming to redefine modern healthcare by removing barriers to care [6] - The platform is designed to empower healthcare providers with AI-powered tools, enabling high-quality care delivery, particularly in underserved and remote areas across North America [6][10] - Treatment.com AI is focused on improving healthcare efficiency through its Global Library of Medicine, which supports healthcare professionals by reducing administrative burdens and enhancing patient care quality [10]

Financial Performance - Total revenues for Q1 2025 were $44,810,000, representing a 9.0% increase from $41,052,000 in Q1 2024[18] - Net loss for Q1 2025 was $10,136,000, compared to a net loss of $5,848,000 in Q1 2024, indicating a 73.0% increase in losses year-over-year[18] - Operating expenses for Q1 2025 totaled $56,008,000, an increase of 15.4% from $48,537,000 in Q1 2024[18] - The company reported a comprehensive loss of $10,136,000 for Q1 2025, compared to a comprehensive loss of $5,848,000 in Q1 2024[18] - Adjusted EBITDA for Q1 2025 was a loss of $3.8 million, compared to a positive $936,000 in Q1 2024[103] - The net loss for the three months ended March 31, 2025, was $10.1 million, compared to a net loss of $5.8 million for the same period in 2024[128][129] Assets and Liabilities - Total current assets decreased to $122,080,000 as of March 31, 2025, down from $135,128,000 at December 31, 2024, a decline of 9.7%[15] - Total liabilities decreased to $33,909,000 as of March 31, 2025, down from $41,554,000 at December 31, 2024, a reduction of 18.4%[15] - Stockholders' equity decreased to $111,096,000 as of March 31, 2025, from $118,137,000 at December 31, 2024, a decline of 5.9%[15] - Cash and cash equivalents at the end of Q1 2025 were $98,026,000, down from $111,835,000 at the end of Q4 2024, a decrease of 12.3%[22] Revenue Sources - Dealer revenue increased to $40.8 million in Q1 2025, up 13.5% from $36.0 million in Q1 2024[71] - For the three months ended March 31, 2025, approximately 8.5% of the company's revenue was derived from arrangements with car manufacturers to promote vehicle sales through consumer incentives, down from 9.6% for the year ended December 31, 2024[178] - The termination of the partnership with American Express in April 2025, which accounted for approximately 5% of the company's units in the twelve months prior to the termination notice, is expected to negatively impact revenue from manufacturer arrangements[182] Expenses - Cash used in operating activities for Q1 2025 was $(7,895,000), compared to cash provided of $2,049,000 in Q1 2024[22] - Stock-based compensation expense for the three months ended March 31, 2025, totaled $3.3 million, up from $2.6 million in Q1 2024, reflecting a 26.3% increase[63] - Sales and marketing expenses rose by $2.94 million, or 13.3%, to $25.02 million, accounting for 55.8% of revenues compared to 53.8% in 2024[115] - General and administrative expenses increased by $0.6 million, or 6.3%, to $10.08 million, accounting for 22.5% of revenues compared to 23.1% in 2024[119] Market and Economic Conditions - The macroeconomic environment continues to pose challenges, including limited new vehicle inventories and rising vehicle costs, impacting financial results[84] - The company acknowledges that economic conditions affecting consumer demand for automobiles, such as interest rates and inflation, may materially impact its business and financial condition[152] - Consumer prices increased by 9.1% during the twelve months ended June 30, 2022, impacting purchasing behavior and car sales[157] Operational Challenges - The company aims to roll out the TrueCar+ offering, which integrates various car-buying processes into a single platform, but faces technical challenges in scaling this offering[162] - The company is currently unable to effectively respond to rapid changes in technology and consumer demands, which could lead to decreased demand for automobiles on its platform[208] - The company may need to implement further measures to reduce operating costs and improve margins, but success is not guaranteed[200] Dealer Relationships - The company relies significantly on revenues from TrueCar Certified Dealers, and failure to maintain or increase these revenues would harm financial performance[164] - The company has observed a decrease in independent dealers due to industry consolidations and financial pressures, which may affect dealer network stability[170] - The company’s ability to attract manufacturers to participate in incentive programs is critical, as failure to do so could reduce growth and harm operating results[179] Strategic Initiatives - In June 2023, the company announced a strategic restructuring plan, resulting in a workforce reduction of approximately 24%[199] - The company is focused on enhancing its software ecosystem and improving customer acquisition efficiency[80] - The company has fully impaired the right-of-use asset associated with a lease amounting to $6.8 million as of March 31, 2025[55]

TrueCar (TRUE) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Company Participants Jantoon Reigersman - President & CEONaved Khan - Managing Director - Equity ResearchOliver Foley - Chief Financial OfficerJash Patwa - Equity Research AssociateMarvin Fong - Director Conference Call Participants Ryan Meyers - Senior Research AnalystTom white - Managing Director, Senior Equity AnalystChris Pierce - Senior Analyst Operator Good day, and welcome to the TrueCar First Quarter twenty twenty five Financial Results C ...

TrueCar (TRUE) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Speaker0 Good day, and welcome to the TrueCar First Quarter twenty twenty five Financial Results Conference Call. Please note that this event is being recorded. I would now like to turn the conference back over to Jantoon Reigersmann, President and Chief Executive Officer of TrueCar. Please go ahead. Speaker1 Thank you, operator. Hello, everyone, and welcome to TrueCar's first quarter twenty twenty five earnings conference call. Joining me today ...

SUPPLEMENTAL MATERIALS First Quarter 2025 Quarter Ended March 31, 2025 SUPPLEMENTAL MATERIALS Important Information This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including our expectations regarding future expected revenue growth and free cash flow, are forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions that may prove incorrect, any of whi ...

Company Performance - TrueCar reported a quarterly loss of $0.09 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.04 per share a year ago [1] - The company posted revenues of $44.81 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 1.91%, and showing an increase from $41.05 million year-over-year [2] - TrueCar shares have declined approximately 58.2% since the beginning of the year, while the S&P 500 has decreased by only 3.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $47.26 million, and for the current fiscal year, it is -$0.14 on revenues of $198.53 million [7] - The estimate revisions trend for TrueCar is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Internet - Services industry, to which TrueCar belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Total revenue for Q1 2025 was $44.8 million, representing a year-over-year increase of $3.8 million (+9.2%) [5] - Net loss increased to -$10.1 million, compared to -$5.8 million in the same period last year [5] - Adjusted EBITDA decreased to -$3.8 million from $0.9 million in the same period last year [5] - Revenue for Q1 2025 was $44.8 million, a 9.2% increase year-over-year from $41.1 million in Q1 2024, but a 3.0% decrease from $46.2 million in Q4 2024 [54][60] - Net loss for Q1 2025 was ($10.1 million), compared to ($5.8 million) in both Q1 2024 and Q4 2024 [54][56] - Adjusted EBITDA for Q1 2025 was ($3.8 million), down from $0.9 million in Q1 2024 [54][56] - Total costs and operating expenses increased to $56,008 thousand, up 15.4% from $48,537 thousand year-over-year [102] - Net loss for the period was $10,136 thousand, compared to a net loss of $5,848 thousand in the same quarter of the previous year, representing a 73.0% increase in losses [102] - Adjusted EBITDA for the three months ended March 31, 2025, was $407 thousand, a significant improvement from a loss of $3,802 thousand in the same period of 2024 [107] Sales and Market Performance - New unit sales volume increased by 23% year-over-year, significantly outpacing the industry's growth of 6.8% in new vehicle retail sales for the quarter [5] - Total units sold in Q1 2025 were 86,000, a 9.3% increase year-over-year but a 7.7% decrease sequentially [70] - Total dealer revenue grew by $4.8 million (+13.3%) year-over-year, driven by a $1.7 million (+6.2%) increase in franchise dealer revenue [61] - OEM revenue for Q1 2025 was $3.8 million, a decline of $1.1 million (-22.4%) year-over-year [62] - Approximately one-third of the pilot dealer group's TrueCar-enabled sales were driven by TC+ consumers completing transactions online [3] Inventory and Financing - The average new vehicle inventory reached 2.7 million units, a decrease of 198 thousand units (-6.7%) quarter-over-quarter but an increase of 248 thousand units (+9.9%) year-over-year [25] - The average APR for new vehicle loans increased to 6.9% in Q1 2025, up from 6.6% in Q4 2024 [16] - The 25% tariffs on imported vehicles are estimated to add approximately $4,500 in additional costs per new vehicle sold in the US, equating to roughly 10% of the average pre-tariff new vehicle MSRP [7] Expenses and Cash Flow - Technology and development expenses totaled $8.1 million in Q1 2025, up 0.0% year-over-year [75] - General and administrative expenses were $10.1 million on a GAAP basis, up 6.3% YoY, and $7.8 million on a non-GAAP basis, up 4.2% YoY in Q1 2025 [76] - Sales and marketing expenses were $25.0 million on a GAAP basis, up 13.3% YoY, and $24.5 million on a non-GAAP basis, up 14.5% YoY in Q1 2025 [81] - TrueCar.com acquisition expense was $4.3 million, down 19.8% YoY, while cost per sale for TrueCar.com units was $170, down 11.9% YoY [82] - Partner marketing spend was $9.2 million, up 21.4% YoY, driven by a 19.1% YoY growth in units attributed to the partner network [82] - Cash and equivalents as of March 31, 2025, were $98.0 million, with no debt [55][56] - The company ended Q1 2025 with $98.0 million in cash and equivalents, down from $133.7 million at the end of Q1 2024 [83] - Cash usage included a $4 million payment to former equity holders of Digital Motors and a $1.4 million one-time payment to American Express [83] - Free cash flow for the three months ended March 31, 2025, was $(10,570) thousand, compared to $4,146 thousand in the previous quarter, reflecting a significant decrease [110] - The company reported a net cash used in operating activities of $(7,895) thousand for the period, compared to $2,049 thousand in the same quarter of 2024 [110] Strategic Initiatives - The company aims to complete back-end integrations with two dealer management system providers by the end of July 2025 [6] - TrueCar aims to enhance its growth strategy by improving lead quality through artificial intelligence and machine learning [91] - The company is focused on developing and scaling its TrueCar+ product to allow dealers to sell more inventory online [91] - TrueCar's management will host a call on May 6, 2025, to discuss financial results and business developments [84] Asset and Liability Management - Cash and cash equivalents decreased to $98,026 thousand as of March 31, 2025, down from $111,835 thousand at the end of 2024, reflecting a decline of 12.3% [104] - Total assets decreased to $145,005 thousand as of March 31, 2025, down from $159,691 thousand at the end of 2024, a reduction of 9.2% [104] - Total liabilities decreased to $33,909 thousand, down from $41,554 thousand at the end of 2024, indicating a decline of 18.4% [104]